Phase 3 Readout

Phase 3 Topline: A Phase 3, Multicenter, Open-label, Long-term Trial Evaluating the Long-term Safety and Tolerability

Indication
Attention Deficit/Hyperactivity Disorder

Other upcoming events for NYMXF

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evalua
Phase 3 ReadoutPhase 3 Topline: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy an
Phase 3 ReadoutPhase 3 Topline: A Phase Ⅲ Randomized, Parallel-group, Placebo-controlled Trial to Assess the Efficacy, Safety of the
Phase 3 ReadoutPhase 3 Topline: A Multicenter, Randomized, Double-blind, Active-Controlled, Parallel, Phase Ⅲ Study to Evaluate the
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Anti-Tumo

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Multicenter, Open-label, Long-term Trial Evaluating the Long-term Safety and Tolerability — NYMXF Phase 3 Readout | BioSniper